137.27 USD
+0.93 (+0.68%)
Last: Feb 10, 2026, 01:50 PM
Taking everything into account, TMDX scores 6 out of 10 in our fundamental rating. TMDX was compared to 186 industry peers in the Health Care Equipment & Supplies industry. TMDX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TMDX is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make TMDX a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
- TMDX had positive earnings in the past year.
- TMDX had a positive operating cash flow in the past year.
- In the past 5 years TMDX reported 4 times negative net income.
- In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
- TMDX has a better Return On Assets (9.70%) than 93.55% of its industry peers.
- With an excellent Return On Equity value of 25.84%, TMDX belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
- TMDX has a Return On Invested Capital of 8.75%. This is amongst the best in the industry. TMDX outperforms 88.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 16.20%, TMDX belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
- With an excellent Operating Margin value of 16.94%, TMDX belongs to the best of the industry, outperforming 87.63% of the companies in the same industry.
- TMDX's Gross Margin of 60.28% is fine compared to the rest of the industry. TMDX outperforms 61.83% of its industry peers.
- TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TMDX is destroying value.
- Compared to 1 year ago, TMDX has more shares outstanding
- The number of shares outstanding for TMDX has been increased compared to 5 years ago.
- The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
- TMDX has an Altman-Z score of 5.77. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
- TMDX has a better Altman-Z score (5.77) than 81.18% of its industry peers.
- TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 4.24, TMDX belongs to the best of the industry, outperforming 80.11% of the companies in the same industry.
- A Debt/Equity ratio of 1.43 is on the high side and indicates that TMDX has dependencies on debt financing.
- The Debt to Equity ratio of TMDX (1.43) is worse than 77.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.77 |
ROIC/WACC0.93
WACC9.43%
2.3 Liquidity
- TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of TMDX (7.69) is better than 88.17% of its industry peers.
- TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
- TMDX has a better Quick ratio (7.13) than 89.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 162.77% over the past year.
- TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.20%.
- TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
- The Earnings Per Share is expected to grow by 33.25% on average over the next years. This is a very strong growth
- Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 21.23% on average per year.
EPS Next Y163.58%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue Next Year39.6%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 55.57, which means the current valuation is very expensive for TMDX.
- Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 67.74% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.06. TMDX is valued rather expensively when compared to this.
- With a Price/Forward Earnings ratio of 46.46, TMDX can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than the industry average as 68.28% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.86, TMDX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.57 | ||
| Fwd PE | 46.46 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 67.20% of the companies in the same industry.
- 75.81% of the companies in the same industry are more expensive than TMDX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.9 | ||
| EV/EBITDA | 38.66 |
4.3 Compensation for Growth
- TMDX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.35% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%
5. Dividend
5.1 Amount
- TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TMDX (2/10/2026, 1:50:28 PM)
137.27
+0.93 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners111.19%
Inst Owner Change-1.39%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.69B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.92 (8.49%)
Short Float %21.95%
Short Ratio9.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)0.06%
PT rev (3m)-0.27%
EPS NQ rev (1m)-0.23%
EPS NQ rev (3m)1.65%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)10.47%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)0.55%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 55.57 | ||
| Fwd PE | 46.46 | ||
| P/S | 8.28 | ||
| P/FCF | 38.9 | ||
| P/OCF | 26.3 | ||
| P/B | 13.21 | ||
| P/tB | 13.73 | ||
| EV/EBITDA | 38.66 |
EPS(TTM)2.47
EY1.8%
EPS(NY)2.95
Fwd EY2.15%
FCF(TTM)3.53
FCFY2.57%
OCF(TTM)5.22
OCFY3.8%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.34
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.77 |
F-Score7
WACC9.43%
ROIC/WACC0.93
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.58%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.6%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
Can you provide the valuation status for TRANSMEDICS GROUP INC?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
How financially healthy is TRANSMEDICS GROUP INC?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.